| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003981 | American Journal of Ophthalmology | 2010 | 9 Pages |
Abstract
Our high reported incidence for this potentially devastating complication can be attributed to multiple factors, including coexisting medical immunocompromising comorbidities, a higher dose with a longer duration of local immunosuppression in the vitreous, multiple injections, as well as previous viral retinitis. Caution with a high index of clinical suspicion and frequent follow-up is advised in patients receiving IVTA injection with potentially immune-altering conditions, even after apparent immune recovery.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ankur M. Shah, Stephen F. Oster, William R. Freeman,